February 23, 2009 - Fresno Heart and Surgical Hospital of Fresno, CA today signed a trial agreement for Daxor Corp's Blood Volume Analyzer BVA-100, for its nuclear medicine department.
“A measured blood volume will provide a state-of-the-art diagnostic tool to diagnose and then treat fluid and blood requirements of our patients,” said Kevin Boran, M.D., a cardiologist from the Fresno Heart and Surgical Hospital’s Congestive Heart Failure Improvement Program. “We intend to utilize this diagnostic tool to contribute to improved outcomes and a reduction in the cost of care as it relates to our patients' fluid needs.”
Daxor manufactures and markets the BVA-100, a semi-automated blood volume analyzer. The BVA-100 is used in conjunction with Volumex, Daxor’s single use diagnostic kit.
Fresno Heart & Surgical Hospital is a full service acute care hospital devoted to cardiovascular and surgical care with 57 beds, including a nine-bed intensive care unit. In addition to cardiac, vascular, bariatric and general surgery in state-of-the-art surgical suites, Fresno Heart and Surgical Hospital also provides specialized cardiac catheterization and vascular interventional rooms, a cardiac evaluation center, and a complete imaging center and clinical laboratory for comprehensive diagnostic services for both inpatient and outpatient services.
The hospital has made a major commitment to develop the largest dedicated congestive heart failure management program in central California. A specially trained team of nurses and technicians work closely with physicians to manage patients with chronic heart failure on an outpatient basis to avoid recurrent hospital admissions. The ability to measure blood volume will find great utility within this specialized program.
For more information: www.Daxor.com
August 15, 2024 
